Skip to main content

Table 1 Primary diagnosis and prior anti-cancer treatment

From: A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors

Number (%) of patientsMogamulizumab 1 mg/kg + Utomilumab, by Dose Group
1.2 mg/kg
n = 11
100 mg
n = 6
2.4 mg/kg
n = 4
5 mg/kg
n = 3
Total
n = 24
CRC10102
NSCLC261110
Ovarian Cancer00011
SCCHN802111
Prior anti-cancer drug regimens
 11 (9.1)01 (25.0)02 (8.3)
 23 (27.3)3 (50.0)006 (25.0)
 32 (18.2)2 (33.3)1 (25.0)3 (100.0)8 (33.3)
  ≥ 45 (45.5)1 (16.7)2 (50.0)08 (33.3)
  1. CRC Colorectal cancer, NSCLC Non-small-cell lung cancer, SCCHN Squamous cell cancer of head and neck